Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Glaxosmithkline Plc (GSK) NYSE

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 95,133,384
  • Shares Outstanding, K 2,437,770
  • Annual Sales, $ 36,578 M
  • Annual Income, $ 12,877 M
  • 36-Month Beta 0.90
  • Price/Sales 2.52
  • Price/Book 17.99

Price Performance

See More
Period Period Low Period High Performance
1-Month
38.09 +1.65%
on 12/22/16
39.79 -2.69%
on 01/05/17
+0.42 (+1.10%)
since 12/20/16
3-Month
37.20 +4.09%
on 12/08/16
41.25 -6.13%
on 10/21/16
-2.71 (-6.54%)
since 10/20/16
52-Week
37.20 +4.09%
on 12/08/16
45.58 -15.05%
on 08/02/16
-0.23 (-0.59%)
since 01/20/16

Most Recent Stories

More News
Is GlaxoSmithKline (GSK) a Great Stock for Value Investors?

Value investing is easily one of the most popular ways to find great stocks in any market environment.

ASQ Names 18 Fellows for Contributions and Achievements to Quality

ASQ recently has named 18 members as Fellows for their achievements and contributions to the advancement of quality. The new Fellows will be recognized at ASQ's World Conference on Quality and Improvement...

Milner Therapeutics Institute Announces New Partnership with US Pharmaceutical Company Pfizer

Pfizer joins Astex, AstraZeneca, GlaxoSmithKline, Shionogi, MedImmune and Otsuka in the Milner Therapeutics Consortium

Chi-Med appoints Industry Veteran Paul Carter to Board of Directors

Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) today announces with effect from February 1, 2017, Mr Paul Rutherford Carter has been appointed as Senior Independent Non-Executive...

Monoclonal Antibody Therapeutics Market to be Worth US$245.8 Billion by 2024: Spike in Cancer Cases Around the World to Ensure Swift Uptake, Predicts TMR

ALBANY, New York, January 12, 2017 /PRNewswire/ --

Monoclonal Antibody Therapeutics Market to be Worth US$245.8 Billion by 2024: Spike in Cancer Cases Around the World to Ensure Swift Uptake, Predicts TMR

Several market players are collaborating with local and well-established companies and research facilities to strengthen their position. Transparency Market Research has observed that companies will continue...

Merck: Keytruda+Chemo Gets Priority Review for Lung Cancer

Merck & Co., Inc.'s (MRK) supplemental Biologics License Application (sBLA) for its anti-PD-1 therapy, Keytruda, has been accepted under priority review by the FDA.

GlaxoSmithKline Partnering Deals and Alliances 2010 to 2016

The Partnering Deals and Alliance since 2010 report provides an in-depth insight into the partnering activity of one of the world's leading life sciences companies.

Bristol-Myers, GeneCentric Tie Up for Opdivo Biomarker Study

Bristol-Myers (BMY) and GeneCentric Diagnostics inked an exploratory biomarker research collaboration.

Bristol-Myers, J&J Ink Immunotherapy Research Collaboration

Bristol-Myers (BMY) entered into an immunotherapy clinical research collaboration with Johnson & Johnson to evaluate a combination of Opdivo and Darzalex.

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More

Business Summary

GlaxoSmithKline is one of the world's leading research based pharmaceutical and healthcare companies and is committed to improving the quality of human life by enabling people to do more, feel better and live longer. They also have leadership in four major therapeutic areas: anti-infectives, central...

See More

Support & Resistance

2nd Resistance Point 38.87
1st Resistance Point 38.80
Last Price 38.72
1st Support Level 38.60
2nd Support Level 38.47

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.